H. Lundbeck Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Charl van Zyl

Chief executive officer

DKK 39.6m

Total compensation

CEO salary percentage	6.8%
CEO tenure	1.3yrs
CEO ownership	n/a
Management average tenure	2.3yrs
Board average tenure	3.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Charl van Zyl's remuneration changed compared to H. Lundbeck's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	DKK 3b
Jun 30 2024	n/a	n/a	DKK 3b
Mar 31 2024	n/a	n/a	DKK 2b
Dec 31 2023	DKK 40m	DKK 3m	DKK 2b

Compensation vs Market: Charl's total compensation ($USD5.50M) is above average for companies of similar size in the UK market ($USD3.50M).

Compensation vs Earnings: Insufficient data to compare Charl's compensation with company performance.

CEO

Charl van Zyl (57 yo)

1.3yrs

Tenure

DKK 39,600,000

Compensation

Mr. Charl van Zyl served as Executive Vice President Neurology Solutions & Head of EU/International at UCB SA since February 2020 until June 2023. He serves as President and Chief Executive Officer of H. L...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Charl van Zyl	President & CEO	1.3yrs	DKK 39.60m	no data
Joerg Hornstein	CFO & Executive VP of Corporate Functions	2.3yrs	DKK 10.90m	0.0023% DKK 891.0k
Lars Bang	Executive Vice President of Product Development & Supply	5.9yrs	DKK 10.10m	0.038% DKK 15.0m
Per Luthman	Executive Vice President of Research & Development	5.9yrs	DKK 11.30m	0.014% DKK 5.5m
Tarek Samad	Senior VP & Head of Research	3.6yrs	no data	no data
Palle Olesen	Chief Specialist & VP of Investor Relations	no data	no data	no data
Tine Hansen	Senior Vice President of Corporate Communications & Public Affairs	less than a year	no data	no data
Dianne Holto	Executive Vice President of People & Culture	less than a year	no data	no data
Ole Chrintz	Senior Vice President of International Markets	no data	no data	no data
Rupert Sandbrink	Senior VP & Head of Clinical Development	2.9yrs	no data	no data
Bjorn Mogensen	Senior Vice President of Group Finance	2.3yrs	no data	no data
Jose Molinuevo	VP & Head of Experimental Medicine	no data	no data	no data

2.3yrs

Average Tenure

58.5yo

Average Age

Experienced Management: HLUNBC's management team is considered experienced (2.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Lars Rasmussen	Independent Chairman	11.9yrs	DKK 1.70m	0.010% DKK 4.0m
Lene Skole-Sorensen	Deputy Chairman	9.9yrs	DKK 1.20m	0.0062% DKK 2.4m
Jeffrey Berkowitz	Independent Director	6.8yrs	DKK 1.20m	no data
Lars Holmqvist	Director	9.9yrs	DKK 600.00k	0.0076% DKK 3.0m
Jakob Riis	Director	1.8yrs	DKK 450.00k	0.0055% DKK 2.1m
Ilse Wenzel	Independent Director	3.8yrs	DKK 70.00k	no data
Santiago Arroyo	Independent Director	3.8yrs	DKK 1.00m	no data
Camilla Andersson	Employee Representative Director	2.8yrs	DKK 400.00k	0.00010% DKK 39.2k
Dorte Clausen	Employee Representative Director	2.8yrs	DKK 400.00k	0.00011% DKK 43.2k
Hossein Armandi	Employee Representative Director	2.8yrs	DKK 400.00k	no data
Lasse Skibsbye	Employee Representative Director	2.8yrs	DKK 400.00k	no data

3.8yrs

Average Tenure

58yo

Average Age

Experienced Board: HLUNBC's board of directors are considered experienced (3.8 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/19 08:37
End of Day Share Price	2024/11/13 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

H. Lundbeck A/S is covered by 39 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Peter Ankersen	ABG Sundal Collier
Kamla Singh	AlphaValue
Charles Pitman	Barclays

H. Lundbeck Management

Management criteria checks 2/4

Key information

Recent management updates

H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024

Less than half of directors are independent

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

Recent updates

H. Lundbeck A/S Announces Positive Results from the Resolve Trial

H. Lundbeck Initiates a Phase III Trial with Amlenetug for the Treatment of Multiple System Atrophy

H. Lundbeck A/S Raises Earnings Guidance for the Year 2024

H. Lundbeck A/S Announces Positive Results from Phase III Pivotal Trial (Sunrise) of Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S Initiates Clinical Trial in Immunology for Lu Ag22515 in Thyroid Eye Disease

H. Lundbeck A/S Presents Results from Two Studies in Multiple System Atrophy at International Congress of Parkinson's Disease and Movement Disorders

Lundbeck and Otsuka Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder

H. Lundbeck A/S Expands Focus on Neurohormonal Dysfunctions with New Cushing's Disease Trial

Lundbeck Presents Innovative First in Human Trial Design of Lu AG13909 for Potential Treatment of Congenital Adrenal Hyperplasia

H. Lundbeck A/S to Report Q4, 2024 Results on Feb 05, 2025

H. Lundbeck A/S Provides Earnings Guidance for the Year 2024

H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024

Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD

Less than half of directors are independent

Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage

H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

Lundbeck Announces Supportive Phase II Results with Lu Af82422 in the Treatment of Multiple System Atrophy from the Amulet Trial

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces New Clinical Data Supporting the Efficacy and Tolerability of Lu AG09222 for the Preventive Treatment of Migraine At the International Headache Congress 2023 in Seoul, Korea

Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

H. Lundbeck A/S to Report Q4, 2023 Results on Feb 07, 2024

H. Lundbeck A/S Raises Earnings Guidance for the Year 2023

H. Lundbeck A/S Appoints Charl Van Zyl as New President

H. Lundbeck A/S Announces New Data Confirming Long-Term Benefit of Treatment with Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S and Otsuka Pharmaceutical, Co. Ltd. Announce U.S. Food and Drug Administration Approval of sNDA for Rexulti®? (Brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer's Disease

H. Lundbeck A/S Proposes Dividend for 2022

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2023

H. Lundbeck A/S Appoints Thomas Gibbs as Executive Vice President and Head of Lundbeck in United States

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S Announce FDA Acceptance and Priority Review of sNDA for Brexpiprazole for the Treatment of Agitation Associated With Alzheimer’s Dementia

H. Lundbeck A/S to Report Nine Months, 2023 Results on Nov 08, 2023

H. Lundbeck A/S, Annual General Meeting, Mar 21, 2023

H. Lundbeck A/S (Lundbeck)Announces Positive Data Showing Trintellix/Brintellix® (vortioxetine)

Otsuka and Lundbeck Announce U.S. FDA Acceptance of New Drug Application for Aripiprazole 2-Month, Ready-To-Use, Long-Acting Injectable to Treat Schizophrenia and Bipolar I Disorder in Adults

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2022

H. Lundbeck A/S Revises Earnings Guidance for the Fiscal Year 2022

H. Lundbeck A/S and Otsuka Pharmaceutical Announce Positive Results Showing Reduced Agitation in Patients with Alzheimer's Dementia Treated with Brexpiprazole

European Medicines Agency Commences Review of Aripiprazole 2-Month Long-Acting Injectable for the Maintenance Treatment of Schizophrenia in Adult Patients Stabilised with Aripiprazole

H. Lundbeck A/S Announces Results from the Deliver Study with Vyepti

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources